4.8 Editorial Material

Crowd sourcing in drug discovery

Journal

NATURE REVIEWS DRUG DISCOVERY
Volume 10, Issue 4, Pages 241-242

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3412

Keywords

-

Funding

  1. Medical Research Council [MC_G1000806] Funding Source: Medline
  2. MRC [MC_G1000806] Funding Source: UKRI
  3. Medical Research Council [MC_G1000806] Funding Source: researchfish

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Medicine, General & Internal

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Marc Feldmann, Ravinder N. Maini, James N. Woody, Stephen T. Holgate, Gregory Winter, Matthew Rowland, Duncan Richards, Tracy Hussell

LANCET (2020)

Article Rheumatology

Base of thumb osteoarthritis in UK interface services-a cohort and survey-based study to assess current practice

Benjamin J. F. Dean, Stefan Kluzek, Andrew J. Carr, Sally Hopewell, Duncan Richards, Nicholas Riley, Andrew Cuff

Summary: Objective Base of thumb OA (BTOA) is a common age-related disease that has a significant negative impact on quality of life. Most UK interface centres have local guidelines and standardized treatment regimes, but lack standardization in terms of injection therapy. Most BTOA patients in interface services have not received comprehensive multimodal intervention.

RHEUMATOLOGY (2021)

Article Surgery

Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes

Omair A. Shariq, Kate E. Lines, Katherine A. English, Bahram Jafar-Mohammadi, Philippa Prentice, Ruth Casey, Benjamin G. Challis, Andreas Selberherr, Hannah Boon, Treena Cranston, Fiona J. Ryan, Radu Mihai, Ultan Healy, Tom Kurzawinski, Mehul T. Dattani, Irina Bancos, Benzon M. Dy, Melanie L. Lyden, William F. Young, Travis J. McKenzie, Duncan Richards, Rajesh V. Thakker

Summary: This study found that 80% of patients with multiple endocrine neoplasia type 1 developed endocrine tumors before the age of 18, including parathyroid tumors, pancreaticoduodenal neuroendocrine tumors, and pituitary tumors. The choice of surgical approach significantly impacted treatment outcomes.

SURGERY (2022)

Article Critical Care Medicine

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Timothy S. C. Hinks, Lucy Cureton, Ruth Knight, Ariel Wang, Jennifer L. Cane, Vicki S. Barber, Joanna Black, Susan J. Dutton, James Melhorn, Maisha Jabeen, Phil Moss, Rajendar Garlapati, Tanya Baron, Graham Johnson, Fleur Cantle, David Clarke, Samer Elkhodair, Jonathan Underwood, Daniel Lasserson, Ian D. Pavord, Sophie Morgan, Duncan Richards

Summary: In this study, adding azithromycin to standard care treatment did not reduce the risk of subsequent hospital admission or death in patients with mild-to-moderate COVID-19 who were managed without hospital admission.

LANCET RESPIRATORY MEDICINE (2021)

Article Cardiac & Cardiovascular Systems

Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Ashutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, Mats Bergstrom, Swethajit Biswas, Chao Chen, Joseph Cheriyan, Matthew Cleveland, Louise Cookson, Paul Galette, Robert L. Janiczek, Raymond Y. Kwong, Mary Ann Lukas, Helen Millns, Duncan Richards, Ian Schneider, Scott D. Solomon, Jens Sorensen, James Storey, Douglas Thompson, Guus van Dongen, Danielle J. Vugts, Anders Wall, Gerhard Wikstrom, Rodney H. Falk

Summary: This study reports the results of a Phase 2 trial using the SAP depleter miridesap and dezamizumab in the treatment of cardiac amyloidosis. The results showed that dezamizumab had no significant effect on improving cardiac function or removing cardiac amyloid deposits. Furthermore, treatment-associated rash and vasculitis were observed in the study.

BMC CARDIOVASCULAR DISORDERS (2022)

Article Critical Care Medicine

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST) : a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Benjamin A. Fisher, Tonny Veenith, Daniel Slade, Charlotte Gaskell, Matthew Rowland, Tony Whitehouse, James Scriven, Dhruv Parekh, Madhu S. Balasubramaniam, Graham Cooke, Nick Morley, Zoe Gabriel, Matthew P. Wise, Joanna Porter, Helen McShane, Ling-Pei Ho, Philip N. Newsome, Anna Rowe, Rowena Sharpe, David R. Thickett, Julian Bion, Simon Gates, Duncan Richards, Pamela Kearns

Summary: This study aimed to evaluate the efficacy of two drugs in hospitalized patients with COVID-19. The results showed that namilumab was able to reduce the inflammatory response, while infliximab did not show significant efficacy compared to usual care. Although there were some differences in adverse events and mortality rates, these differences were not significant.

LANCET RESPIRATORY MEDICINE (2022)

Article Primary Health Care

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial

Jienchi Dorward, Ly-Mee Yu, Gail Hayward, Benjamin R. Saville, Oghenekome Gbinigie, Oliver Van Hecke, Emma Ogburn, Philip H. Evans, Nicholas P. B. Thomas, Mahendra G. Patel, Duncan Richards, Nicholas Berry, Michelle A. Detry, Christina Saunders, Mark Fitzgerald, Victoria Harris, Milensu Shanyinde, Simon de Lusignan, Monique Andersson, Christopher C. Butler, F. D. Richard Hobbs

Summary: This study aimed to determine the effects of colchicine on recovery time and hospitalization/death related to COVID-19. The results showed that colchicine did not reduce recovery time or decrease the risk of hospitalization/death related to COVID-19 among participants in the community.

BRITISH JOURNAL OF GENERAL PRACTICE (2022)

Article Multidisciplinary Sciences

COVID-19 therapeutics: Challenges and directions for the future

Philip C. Robinson, David F. L. Liew, Helen L. Tanner, John R. Grainger, Raymond A. Dwek, Ronald B. Reisler, Lawrence Steinman, Marc Feldmann, Ling-Pei Ho, Tracy Hussell, Paul Moss, Duncan Richards, Nicole Zitzmann

Summary: The emergence of SARS-CoV-2 and the resulting COVID-19 pandemic have had a significant impact on global society. While substantial investment in life sciences has led to rapid advancements in viral characterization, testing, and the development of highly effective vaccines, drug treatments for COVID-19 have been limited. Innovative approaches in clinical trials and repurposing existing drugs have saved lives, but there is still a need for further development of therapeutics. It is important to address the challenges and unmet needs in order to prepare for future pandemics and ensure the cost-effective development and equitable distribution of new therapeutics.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Correction Surgery

Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes (vol 171, pg 77, 2021)

Omair A. Shariq, Kate E. Lines, Katherine A. English, Bahram Jafar-Mohammadi, Philippa Prentice, Ruth Casey, Benjamin G. Challis, Andreas Selberherr, Hannah Boon, Treena Cranston, Fiona J. Ryan, Radu Mihai, Ultan Healy, Tom Kurzawinski, Mehul T. Dattani, Irina Bancos, Benzon M. Dy, Melanie L. Lyden, William F. Young, Travis J. McKenzie, Duncan Richards, Rajesh V. Thakker

SURGERY (2022)

Article Genetics & Heredity

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

Duncan Richards, Helen Millns, Louise Cookson, Mary Ann Lukas

Summary: This is a long-term follow-up study of patients with amyloidosis treated with miridesap/dezamizumab, showing progressive amyloid removal in some patients after less than 3 cycles of treatment. The functional, cardiac, laboratory, and imaging assessments of the responding patients were analyzed, providing insights for the long-term follow-up of these patients.

ORPHANET JOURNAL OF RARE DISEASES (2022)

Article Biotechnology & Applied Microbiology

Predictive validity in drug discovery: what it is, why it matters and how to improve it

Jack W. Scannell, James Bosley, John A. Hickman, Gerard R. Dawson, Hubert Truebel, Guilherme S. Ferreira, Duncan Richards, J. Mark Treherne

Summary: This article discusses the impact of predictive validity on R&D productivity and emphasizes its importance in the evaluation of therapeutic candidates. Through analysis based on decision theory and historical data, it reveals the underestimation of predictive validity in drug development.

NATURE REVIEWS DRUG DISCOVERY (2022)

Review Medicine, Research & Experimental

In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review

Philip G. Drennan, Dimitrios Karponis, Duncan Richards, Mark Coles, James N. Fullerton

Summary: This systematic review surveyed published literature on the use of keyhole limpet hemocyanin (KLH) as a challenge agent in humans. It found that there is currently no standardized approach to the design and conduct of studies using KLH. The review identified issues with incomplete description of challenge regimens and lack of utilization of mechanism-relevant endpoints. Future standardization and methodological development is needed to optimize drug development decisions.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Article Medicine, General & Internal

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher C. Butler, F. D. Richard Hobbs, Oghenekome A. Gbinigie, Najib M. Rahman, Gail Hayward, Duncan B. Richards, Jienchi Dorward, David M. Lowe, Joseph F. Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Mahendra G. Patel, Benjamin R. Saville, Joe Marion, Emma Ogburn, Julie Allen, Heather Rutter, Nick Francis, Nicholas P. B. Thomas, Philip Evans, Melissa Dobson, Tracie-Ann Madden, Jane Holmes, Victoria Harris, May Ee Png, Mark Lown, Oliver van Hecke, Michelle A. Detry, Christina T. Saunders, Mark Fitzgerald, Nicholas S. Berry, Lazaro Mwandigha, Ushma Galal, Sam Mort, Bhautesh D. Jani, Nigel D. Hart, Haroon Ahmed, Daniel Butler, Micheal McKenna, Jem Chalk, Layla Lavallee, Elizabeth Hadley, Lucy Cureton, Magdalena Benysek, Monique Andersson, Maria Coates, Sarah Barrett, Clare Bateman, Jennifer C. Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Andrew Carson-Stevens, Ly-Mee Yu, Paul Little

Summary: This study aimed to determine the safety, effectiveness, and cost-effectiveness of molnupiravir in vaccinated high-risk patients in the community. The results showed that molnupiravir did not reduce hospital admissions or deaths associated with COVID-19 compared to usual care in this population.

LANCET (2023)

Meeting Abstract Respiratory System

A RANDOMISED CLINICAL TRIAL OF AZITHROMYCIN VERSUS STANDARD CARE IN AMBULATORY COVID-19-THE ATOMIC2 TRIAL

T. S. C. Hinks, L. Cureton, R. Knight, A. Wang, J. L. Cane, V. S. Barber, J. Black, S. J. Dutton, J. Melhorn, M. Jabeen, P. Moss, R. Garlapati, T. Baron, G. Johnson, F. Cantle, D. Clarke, S. Elkhodair, J. Underwood, D. Lasserson, I. D. Pavord, S. B. Morgan, D. Richards

THORAX (2021)

Article Medicine, General & Internal

CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Tonny Veenith, Benjamin A. Fisher, Daniel Slade, Anna Rowe, Rowena Sharpe, David R. Thickett, Tony Whitehouse, Matthew Rowland, James Scriven, Dhruv Parekh, Sarah J. Bowden, Joshua S. Savage, Duncan Richards, Julian Bion, Pamela Kearns, Simon Gates

Summary: The CATALYST trial aims to identify novel treatments for COVID-19 patients through immunomodulation to improve outcomes. The trial has been approved by the appropriate ethics committee and will disseminate results through national and international presentations and peer-reviewed publications.

BMJ OPEN (2021)

No Data Available